You may remember that not so long ago I wrote about what looked like a drug discovery success story for pain: anti-NGF therapy for osteoarthritis. Well, it looks like that success was short-lived. Somehow I missed this over the Christmas break, but, the FDA has ended trials on anti-NGF therapies for osteoarthritis due to development of avascular necrosis in some patients. Nothing positive can come of avascular necrosis and the pulling of several trials would suggest that this is a drug class effect (or at least suspected to be). Anyway you cut it, this is bad news.
- Short blog post on our work on AMPK activators for chronic pain: bodyinmind.org/ampk-metformin… 11 months ago
- NIH spends less than $0.50 per migraine patient on migraine research americanmigrainefoundation.org/support-the-fo… 1 year ago
- New article by yours truly on Pain Research Forum... What's up with PKMzeta? painresearchforum.org/news/23452-wha… 1 year ago
- or this one: informahealthcare.com/doi/abs/10.310… Thanks a ton 1 year ago
- anyone have access to this? onlinelibrary.wiley.com/doi/10.1016/j.… PDF to juniorprofblog at gmail dot com 1 year ago
- New Facebook page for University of Arizona Department of Pharmacology on.fb.me/OWPl1v 2 years ago
Deborah Davidson on What is hyperalgesia? What is… Kristal on Question lrae2014 on What is hyperalgesia? What is… LAF on What is hyperalgesia? What is… clik here for more on The semester is over!!
- 327,079 fans